China’s Medilink Therapeutics (Suzhou) Co. Ltd. and Germany’s Biontech SE signed another potential $1 billion-plus deal for novel antibody-drug conjugate (ADC) targets, building off the first ADC-based licensing deal from last year.

China’s Medilink Therapeutics (Suzhou) Co. Ltd. and Germany’s Biontech SE signed another potential $1 billion-plus deal for novel antibody-drug conjugate (ADC) targets, building off the first ADC-based licensing deal from last year.

Bristol Myers Squibb Co. has exercised its option for an exclusive global license for PRX-019, a potential treatment of neurodegenerative diseases with an undisclosed target, under an agreement with Prothena Corp. plc.

Owkin Inc. has in-licensed OKN-4395 (ACT-1002-4391), a highly selective and potent dual inhibitor of prostanoid receptors EP2 and EP4, from Idorsia Ltd.

Evergreen Theragnostics Inc. has entered into a collaboration and licensing agreement with the Medical University of Innsbruck (MUI) to advance the development of novel radiopharmaceuticals.

A licensing deal worth potentially up to $1.2 billion with Sanofi SA has breathed new life into Novavax Inc., which has struggled to compete in the COVID-19 space with powerhouses Pfizer Inc. and Moderna Inc.

South Korea’s HK Inno.N Corp. said on May 2 that it gained exclusive development and commercial rights to Hangzhou, China-based Sciwind Biosciences Co. Ltd.’s once-weekly, injectable glucagon-like peptide-1 (GLP-1) agonist, XW-003 (ecnoglutide), in South Korea to treat type 2 diabetes and obesity.

South Korea’s HK Inno.N Corp. said on May 2 that it gained exclusive development and commercial rights to Hangzhou, China-based Sciwind Biosciences Co. Ltd.’s once-weekly, injectable glucagon-like peptide-1 (GLP-1) agonist, XW-003 (ecnoglutide), in South Korea to treat type 2 diabetes and obesity.